Osimertinib elicited a satisfactory intracranial objective response rate (ORR) of 54% and a disease control rate (DCR) of 92% in T790M‐positive NSCLC patients (n = 50) who progressed after prior EGFR TKI intervention.46 The gene discussed is EGFR; the disease is non-small cell lung carcinoma.